Dilan Bio Completes Tens of Millions RMB Series A+ Financing to Advance Fungal Molecular Diagnostics

Fungal infections are a relatively common phenomenon, but in the past, they did not receive sufficient attention due to limitations in technical methods and awareness of personal health. From a technical perspective, traditional fungal detection relies on culture as the gold standard, which is time-consuming and labor-intensive. Microscopic examination, while simple and convenient, has low sensitivity and requires high professional expertise. Biochemical and immunological methods, such as the G-test and GM-test, are widely used but carry a significant risk of false positives and false negatives and cannot identify specific fungal species. The mission of Dylan Biotechnology is to address these market pain points and provide a breakthrough for patients with fungal infections by enabling rapid and precise treatment.

Under the pressure of SARS-CoV-2 infections, invasive fungal diseases (IFDs) have gradually emerged as a growing public health concern in China and globally, attracting increasing attention. As medical mycologists and clinicians place greater emphasis on IFDs, diagnostic capabilities are expected to extend down to secondary hospitals, further unlocking the market potential for invasive fungal diagnostics in China. Due to the high technical barriers and specialized expertise required for the research, development, and production of fungal diagnostic reagents, fungal testing has become an emerging blue-ocean market.

Recently,At a critical stage in its development, Hangzhou Dylan Biotechnology Co., Ltd. (“Dylan Biotech”), a leading enterprise in the field of molecular fungal diagnostics in China, secured tens of millions in investment from Zhejiang Collaborative Innovation Investment Management Co., Ltd. (“Zhejiang Collaborative”) and Hangzhou Jinsheng Group Co., Ltd. (“Jinsheng Group”). Notably, this marked Zhejiang Collaborative’s second investment in the company.The funds raised in this round will be used to expand the product R&D pipeline of Hangzhou Dylan Biotechnology Co., Ltd., which holds full independent intellectual property rights, advance new product registration and market expansion, and establish new production bases to increase manufacturing capacity.

Dylan Biotechnology is the only biotechnology company in China dedicated to the development of molecular diagnostic products for fungal infections. As a pioneer and leader in domestic fungal molecular diagnostic reagents, the company leverages one of the most mature molecular biology techniques—quantitative real-time PCR (qPCR)—and was the first to obtain three Class III IVD product registration certificates from the National Medical Products Administration (NMPA), providing significant support for rapid clinical diagnosis. The application of molecular diagnostics can effectively improve the confirmed diagnosis rate of fungal infections, featuring high sensitivity, strong specificity, and rapid, non-invasive detection. Dylan Biotechnology aims to establish nucleic acid testing as the gold standard for fungal molecular diagnostics.

Dylan Biotechnology continuously drives technological and product innovation, having established a robust R&D team, a comprehensive quality management system, and dedicated teams for clinical trials, regulatory registration, marketing, technical support, and sales, backed by extensive experience in industrialization. Guided by clinically significant pathogens and real-world application scenarios, Dylan Biotechnology designs products that comprehensively cover high-priority pathogens posing substantial health risks, achieving a “broad yet precise” portfolio in the field of mycology. Furthermore, tailored fungal co-detection solutions are developed for respiratory tract infections, bloodstream infections, and central nervous system infections, addressing the diverse needs of various clinical departments and patients with different types of infections.

Liu Xiao’ou, Investment Manager at Zhejiang Xietong“He stated, ‘The high technical barriers associated with molecular diagnostic technologies for fungi underscore the significant uniqueness and exclusivity of this project. As Hangzhou Dylan Biotechnology Co., Ltd. is a pragmatic and execution-driven enterprise, we are highly optimistic about its growth prospects. We also hope that Dylan Biotechnology will accelerate market expansion, leverage its first-mover advantage, and continually consolidate its leading position in the fungal diagnostics industry.’”

Zhou Lian, President of Jinsheng Group“We are deeply honored to have successfully invested in Hangzhou Dylan Biotechnology Co., Ltd. (Dylan Bio) and facilitated its establishment at our Jinsheng Technology Park. We are profoundly impressed by the diligent and excellence-driven work ethic of the team led by Dr. Fang Yuan. Such a team deserves recognition and trust. We hope that our capital empowerment will inject vitality into Dylan Bio’s high-quality development. Furthermore, we aim to position Dylan Bio as a benchmark enterprise within our park, serving as a model for our investment promotion efforts, thereby achieving mutual success.”

In the face of broader market opportunities,Zhang Renyou, Director and Vice President of Hangzhou Dylan Biotechnology Co., Ltd.He stated, “We extend our sincere gratitude to Zhejiang Xietong and Jinsheng Group for their recognition and strong support of Dylan Biotechnology, as well as to all shareholders for their continuous empowerment and assistance. Over the past decade, Dylan Biotechnology has dedicated itself to accumulating expertise in fungal molecular diagnostics, establishing a professional standing in the fungal industry and emerging as an innovative, high-tech biotechnology enterprise focused on this field. Meanwhile, Dylan Biotechnology has established an expert workstation and forged industry-academia-research collaborations with multiple hospitals. We will strengthen collaborative efforts with industry experts to tackle technical challenges, providing more scientific and precise diagnostic products to address clinical pain points. Dylan Biotechnology is poised to set sail and thrive in the emerging blue-ocean market.”

Hangzhou Dylan Biotechnology possesses independent R&D laboratories, quality control laboratories, and GMP-compliant manufacturing facilities. It has established dedicated production lines for its fluorescent PCR reagent series, fungal nucleic acid extraction series, and fungal fluorescent staining solution series, providing robust support for technological R&D, scientific collaboration, product testing, manufacturing, and sales. Adhering to the principle of creating superior products through innovative technologies, the company is committed to developing pathological molecular diagnostic products with independent intellectual property rights that address urgent clinical needs. These products include in vitro diagnostic reagents such as fungal nucleic acid detection kits (fluorescent PCR method), fungal nucleic acid extraction and purification reagents, and fungal immunofluorescence staining solutions (one-step method). The company’s current product development strategy has expanded to cover molecular detection and species-specific identification of the most common pathogens causing invasive fungal infections in China. It is developing a pipeline of fungal detection products across both quantitative real-time PCR (qPCR) and digital PCR (ddPCR) platforms, with a focused effort on building a new “Digital Fungi” product line to provide novel tools for urgently needed clinical quantitative testing and therapeutic monitoring.